Revolutionary X-Ray Sensitizers: Paving the Way for Low-Dose Radiation in Cancer Treatment

Researchers at Xiamen University have made a major breakthrough in cancer treatment with the development of a new class of X-ray-sensitizers (XSs), potentially transforming radiotherapy. Published in Engineering, the study details how organic pharmaceutical drug intermediates derived from thioxanthone (TX) can be activated by low-dose X-rays to efficiently generate singlet oxygen, offering a targeted approach for cancer therapy.

Traditional radiotherapy, a cornerstone of cancer treatment, typically requires high radiation doses (over 50 Gy), which can lead to significant side effects. To reduce these risks, clinicians often use fractionated radiation therapy, where smaller doses (less than 2 Gy) are delivered over multiple sessions. The new research, led by Hongmin Chen’s team, proposes a novel method to boost the effectiveness of these smaller doses, potentially reducing side effects while maintaining or even improving therapeutic outcomes.

The study focuses on TX-derived organic molecules, which have shown remarkable potential in generating singlet oxygen—a highly reactive species capable of selectively destroying cancer cells—under X-ray irradiation. This technique, known as scintillator X-ray-induced photodynamic therapy, uses low-dose X-rays to activate these molecules, providing a more precise and less harmful alternative to traditional radiotherapy.

The researchers screened various TX derivatives and adjusted the alkoxy side chain substitutions at the 2-position of TX to fine-tune their molecular packing and intermolecular interactions. These modifications allowed them to evaluate the fluorescence and room-temperature phosphorescence (RTP) of the TX derivatives under X-ray exposure.

The study found that TX derivatives outperformed phenothiazine derivatives in radioluminescence and efficiently generated singlet oxygen when exposed to low-dose X-rays. This ability to produce singlet oxygen with minimal radiation could reduce the required dose for effective treatment. Both in vitro and in vivo tests confirmed their potential to target tumor cells and enhance cancer therapy. These findings suggest that TX-based molecules could improve low-dose X-ray radiotherapy, boosting efficacy while minimizing side effects.

This innovative approach could revolutionize cancer treatment protocols, offering a more effective and patient-friendly alternative to traditional radiotherapy. With further research, TX-derived X-ray-sensitizers could become a crucial tool in advanced cancer therapies, improving outcomes and reducing patient discomfort.